

Guidance for the management of chemotherapy induced hair loss.

Draft Recommendations.



Number	Recommendation	Grade	References
1	Provision of information about alopecia and the use of wigs and head coverings prior to treatment facilitates coping and adjustment.		Batchelor
2	Patients receiving whole brain radiotherapy, taxanes or high dose chemotherapy should be warned about the low risk of persistent alopecia.		Kluger, Thorp, Lawenda
3	Scalp cooling with gel or coolant systems may be effective in reducing hair loss in up to 50% of women with breast cancer undergoing (neo)adjuvant chemotherapy with taxanes and/or anthracyclines.		Rugo meta-analysis, Rugo, Nangia, van den Hurk, St Gallen Guidelines, Shin Rice
4	Women receiving adjuvant chemotherapy for early breast cancer can be informed that scalp cooling does not appear to increase the risk of scalp metastases or impact on survival.		Rugo meta-analysis, van den Hurk, Lemieux
5	Scalp cooling may be effective in patients with prostate cancer, colorectal cancer, gynaecological malignancies and lung cancer receiving chemotherapy.		Dutch registry van den Hurk 2012

6	Scalp cooling is less effective with long (> 3hours), high dose and multi-day chemotherapy regimens.		Dutch registry
7	There is little evidence to guide effectiveness and safety of scalp cooling in patients with haematological malignancies,		Dutch registry Practice point?
8	Patients undergoing scalp cooling require advice on hair care during treatment to minimise hair breakage.		Shaw 2016
9	Effectiveness of scalp cooling may be influenced by post infusion cooling time, temperature obtained, fitting of the cap, and nursing management.		Practice point, Young 2016, Janssen, Komen
10	Patients should be advised about potential side effects of scalp cooling including cold thermal injury and headache.		Belum, Rugo meta-analysis.

11	<p>Patients with persistent alopecia should be assessed for Iron deficiency, thyroid disorders, zinc deficiency, ovarian hypofunction and immune alopecia.</p>		<p>Expert opinion? Mario</p>
12	<p>More rapid regrowth of scalp hair after chemotherapy has been demonstrated with the use of 2% minoxidil foam.</p>		<p>1 small trial in breast cancer Duvik</p>
13	<p>Persistent alopecia post chemotherapy may respond to oral minoxidil.</p>		<p>Yang small cohort</p>
14	<p>Alopecia caused by endocrine agents in patients with breast cancer may respond to 2% minoxidil foam or oral spironolactone.</p>		<p>1 trial, sagger</p>

15.	Patients should be warned that madarosis has a different time frame to scalp hair loss, and is not prevented by scalp cooling.		Smith 2018, qualitative study.
16.	Patients at risk of madarosis should receive information about eye protection and masking options.		Smith 2018, Batchelor.
17.	Bimatoprost 0.3% eyelash gel may assist recovery from eyelash loss due to chemotherapy		Morris CL 2011. One small study in breast cancer. Ahluwalia 2013